Periodontitis remains one of the most common chronic inflammatory diseases affecting millions globally, characterized by an imbalance in the oral microbiome and prompted by pathogenic bacteria. Due to this imbalance, the body's immune response becomes inefficient, resulting in harm to
Human lips, being complex structures formed of mucosa, skin, and innervated skeletal muscles, are essential for various daily activities such as eating, drinking, talking, and social interactions. This makes their reconstruction, especially after traumatic injuries or cancer surgeries, a
Jim Wilson, a seminal figure in the field of gene therapy, is departing the University of Pennsylvania (UPenn) after an illustrious career spanning decades. His decision to step down marks a significant juncture for both the institution and the broader gene therapy landscape. Over the years, Wilson
The article delves into the escalating scrutiny by US lawmakers on Chinese biotech and medtech companies, which they allege pose significant national security risks. These legislative actions are part of a broader strategy to curb Chinese influence and secure US technology and intellectual
AbbVie's financial performance and strategic initiatives in 2022 demonstrate a concerted effort to drive growth and enhance its presence in the pharmaceutical and biopharmaceutical sectors. With revenues exceeding $58 billion, the year reflected significant advancements fueled by new product
The biopharma industry is abuzz with rumors of a potential takeover of CAR-T specialist Legend Biotech, a company renowned for its collaboration with Johnson & Johnson (J&J) on the BCMA CAR-T therapy Carvykti. An unnamed source cited by StreetInsider has revealed that Legend recently
Synthetic biology, commonly known as synbio, is at the cutting edge of biotechnology, offering revolutionary solutions for various industries. Dr. John Cumbers, a pioneering figure in this field and the Founder and CEO of SynBioBeta LLC, provides profound insights into how synbio can address
The biopharmaceutical industry is witnessing major advancements in cell therapy, with CAR-T therapies surfacing as a pioneering avenue for treating complex diseases. The latest development in this field is the expanded strategic collaboration between IASO Biotechnology (IASO Bio) and Innovent
Sutro Biopharma Inc. (NASDAQ:STRO) has been experiencing a challenging period, marked by considerable stock price fluctuations and substantial revenue declines. This California-based biotech firm, specializing in oncology therapeutics, is grappling with mixed sentiments among investors amidst a
Natural Killer (NK) cell therapy, once a promising beacon for cancer treatment, is now being repositioned as a potential game-changer in the management of autoimmune diseases. Biotech companies, like Artiva Biotherapeutics, are shifting their focus to explore the untapped potential of NK cell
